Arcus Biosciences (RCUS) Cash from Investing Activities (2017 - 2026)

Arcus Biosciences' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $114.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 256.25% year-over-year to $114.0 million; the TTM figure through Mar 2026 stood at $148.0 million (up 26.5% YoY), while the FY2025 annual figure was $66.0 million, up 178.57% from the prior year.
• Cash from Investing Activities was $114.0 million for Q1 2026 at Arcus Biosciences, up from -$182.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $137.0 million in Q2 2025 to a low of -$268.0 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$7.2 million across 5 years, with a median of $28.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities slumped 7259.51% in 2022, then jumped 372.41% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $47.0 million in 2022, then tumbled by 40.43% to $28.0 million in 2023, then jumped by 82.14% to $51.0 million in 2024, then plunged by 456.86% to -$182.0 million in 2025, then jumped by 162.64% to $114.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $114.0 million (Q1 2026), -$182.0 million (Q4 2025), and $79.0 million (Q3 2025), per Business Quant data.